Selvita Initiates Med Chem Collaboration with UCSF
News Aug 10, 2016
Selvita Inc. has initiated a medicinal chemistry collaboration with the University of California, San Francisco (UCSF). The project will be conducted with the Institute for Neurodegenerative Diseases at UCSF. Within the scope of the project, Selvita will be responsible for the chemical synthesis, purification, structure determination, and purity analysis of small molecules for the treatment of neurodegenerative diseases.
The project will focus on the synthesis of new derivatives, constituting potential new therapeutics with improved pharmacological properties. This project was preceded by a thorough evaluation and pilot projects involving medicinal chemistry as well as ADME projects, which Selvita successfully completed. The contract will be carried out from 2016 to 2019.
“We’re truly delighted that such renowned research institutions as the Institute for Neurodegenerative Diseases and the University of California have decided to collaborate with Selvita on this project. This is a great chance for us to show the potential of our scientists, as well as the expertise and capabilities we have as a company,” said Andrzej Nieradka, Business Development Manager at Selvita Inc., who is responsible for managing the collaboration.
Selvita’s San Francisco Bay Area office was founded in San Bruno, CA in September 2015 and is dedicated to the support of Selvita business partners on the West Coast of the US. The office is located at 1001 Bayhill Drive, San Bruno, California.
Neural Computer Hears Like HumansNews
Modelling the human senses is an incredibly complex task. Our brains arrange cells into complex hierarchies that process information from our surroundings. Now, a group at MIT have created a model of the human auditory cortex that can hear sounds and music in the same way that humans do.READ MORE
Stable Beta-Amyloid Dimers Identified in Alzheimer’s BrainsNews
A recent study exploited state-of-the-art mass spectrometry to provide the first direct evidence of beta-amyloid dimers in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers. Beta-amyloid dimers may be the smallest pathological species that trigger Alzheimer’s disease.
Super-Obese People's Hypothalamic Neurons Show Several Genetic Differences to Non-Obese NeuronsNews
Scientists have re-created brain neurons of obese patients using "disease in a dish" technology, offering a new method to study the brain's role in obesity and possibly help tailor treatments to specific individuals.READ MORE
Comments | 0 ADD COMMENT
2nd International Conference and Exhibition on Nanomedicine and Drug Delivery
May 21 - May 23, 2018